… target inhibition on different receptors (Table 2)? This review will present the scientific rationale
for dual inhibition of … to date with a new generation of dual-targeting single-agent drugs. …

… tyrosine kinase inhibitors, … inhibits the recombinant EGFR and HER2 tyrosine kinases by
50% (IC 50 ) at concentrations of 10.8 and 9.3 nmol/l, respectively. It acts as a reversible inhibitor…

… , dual reversible inhibitor of the EGFR and HER2 tyrosine kinases (TKs), was recently approved
by the FDA in combination with capecitabine for the treatment of HER2-… against HER2. …

Background The purpose of this study was to evaluate the efficacy of afatinib in EGFR-mutant
metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib. Materials and …

… through the development of dual EGFR/HER2 inhibitors with improved enzymatic affinities.
… dual EGFR/HER2 inhibitor, Lapatinib, we proposed the design of dual EGFR/HER2 inhibitors …

… 72 h and downregulation of EGFR, HER2, and HER3 was detected … to EGFR and EGFR+HER2
inhibition. Both MCF7 and T47D TamRes cells were sensitive to EGFR and EGFR+HER2 …

… the potential of dual EGFR/HER2 inhibition. Lapatinib, a reversible EGFR/HER2 inhibitor,
has … Here we focus on BIBW 2992, a potent, irreversible inhibitor of both EGFR and HER2 …

… , a small molecule tyrosine kinase inhibitor in a large panel of … HER2-amplified subgroup.
We provide a comparison between isolated EGFR inhibition with erlotinib and HER2 inhibition …

… 1), the second generation irreversible dual EGFR/HER2 inhibitor got approval by FDA for …
actively mutated EGFR. Erlotinib and gefitinib worked on EGFR and not worked on EGFR and …

… HER2 notably with an IC 50 value of 2.28 ± 0.53 μM making it a dual EGFR and HER2 inhibitor.
… out that compound 3f showed high affinity into the ATP binding sites of EGFR and HER2. …